Wierda WG - Search Results

1

Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia.

Claus R, Lucas DM, Ruppert AS, Williams KE, Weng D, Patterson K, Zucknick M, Oakes CC, Rassenti LZ, Greaves AW, Geyer S, Wierda WG, Brown JR, Gribben JG, Barrientos JC, Rai KR, Kay NE, Kipps TJ, Shields P, Zhao W, Grever MR, Plass C, Byrd JC. Claus R, et al. Among authors: wierda wg. Blood. 2014 Jul 3;124(1):42-8. doi: 10.1182/blood-2014-02-555722. Epub 2014 May 27. Blood. 2014. PMID: 24868078 Free PMC article.

2

Chronic lymphocytic leukemia.

Wierda WG, Kipps TJ. Wierda WG, et al. Curr Opin Hematol. 1999 Jul;6(4):253-61. doi: 10.1097/00062752-199907000-00010. Curr Opin Hematol. 1999. PMID: 10400375 Review.

3

CD40 activation does not protect chronic lymphocytic leukemia B cells from apoptosis induced by cytotoxic T lymphocytes.

Chu P, Wierda WG, Kipps TJ. Chu P, et al. Among authors: wierda wg. Blood. 2000 Jun 15;95(12):3853-8. Blood. 2000. PMID: 10845920 Free article.

4

Gene therapy of hematologic malignancies.

Wierda WG, Kipps TJ. Wierda WG, et al. Semin Oncol. 2000 Oct;27(5):502-11. Semin Oncol. 2000. PMID: 11049018 Review.

5

CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia.

Wierda WG, Cantwell MJ, Woods SJ, Rassenti LZ, Prussak CE, Kipps TJ. Wierda WG, et al. Blood. 2000 Nov 1;96(9):2917-24. Blood. 2000. PMID: 11049967 Free article. Clinical Trial.

6

Immunogenetic therapy for B-cell malignancies.

Kipps TJ, Chu P, Wierda WG. Kipps TJ, et al. Among authors: wierda wg. Semin Oncol. 2000 Dec;27(6 Suppl 12):104-9. Semin Oncol. 2000. PMID: 11225994 Review.

7

T cell activation following infection of primary follicle center lymphoma B cells with adenovirus encoding CD154.

Cantwell MJ, Wierda WG, Lossos IS, Levy R, Kipps TJ. Cantwell MJ, et al. Among authors: wierda wg. Leukemia. 2001 Sep;15(9):1451-7. doi: 10.1038/sj.leu.2402208. Leukemia. 2001. PMID: 11516107

8

Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies.

Faderl S, Thomas DA, O'Brien S, Garcia-Manero G, Kantarjian HM, Giles FJ, Koller C, Ferrajoli A, Verstovsek S, Pro B, Andreeff M, Beran M, Cortes J, Wierda W, Tran N, Keating MJ. Faderl S, et al. Blood. 2003 May 1;101(9):3413-5. doi: 10.1182/blood-2002-07-1952. Epub 2003 Jan 9. Blood. 2003. PMID: 12522009 Free article. Clinical Trial.

9

Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy.

Cortes JE, Talpaz M, Giles F, O'Brien S, Rios MB, Shan J, Garcia-Manero G, Faderl S, Thomas DA, Wierda W, Ferrajoli A, Jeha S, Kantarjian HM. Cortes JE, et al. Blood. 2003 May 15;101(10):3794-800. doi: 10.1182/blood-2002-09-2790. Epub 2003 Jan 30. Blood. 2003. PMID: 12560227 Free article. Clinical Trial.

10

Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia.

Wierda WG, Johnson MM, Do KA, Manshouri T, Dey A, O'Brien S, Giles FJ, Kantarjian H, Thomas D, Faderl S, Lerner S, Keating M, Albitar M. Wierda WG, et al. Br J Haematol. 2003 Feb;120(3):452-6. doi: 10.1046/j.1365-2141.2003.04118.x. Br J Haematol. 2003. PMID: 12580959 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

539 results

Search Page

Filters